



Washington State Health Care Authority
Prescription Drug Program

626 8th Ave SE, Olympia, WA 98501 • 206-521-2029

<https://www.hca.wa.gov/about-hca/prescription-drug-program>

7/8/2024

Dear Interested Party,

Based on recommendations by the Washington State Pharmacy and Therapeutics Committee, the Health Care Authority, Uniform Medical Plan (UMP), and the Department of Labor & Industries (L&I) have named the following drugs as preferred in their respective therapeutic classes on the Washington State Preferred Drug List (PDL), effective August 1, 2024:

CGRP Inhibitors reviewed 10/18/2023		Agency Coverage	
Ingredient Name	Label Name of Preferred Product	L&I	UMP
erenumab	Aimovig [®] auto-injection	Not participating	Yes
fremanezumab	Ajovy [®] syringe		Yes
fremanezumab-VFRM	Ajovy [®] auto-injection		Yes
galcanezumab	Emgality [®] syringe		Yes
	Emgality [®] auto-injection		Yes
ubrogepant	Ubrelvy [®] tablet		Yes
The effect of this recommendation is to make Aimovig [®] , Emgality [®] and Ubrelvy [®] preferred on the WA PDL.			

Each agency will use the common PDL according to its benefit structure. You may view the current PDL on our [website](#).

If you have other questions or comments regarding this announcement, please contact Leta Evaskus at (360) 725-1188 or by email at leta.evaskus@hca.wa.gov.

Sincerely,

Donna Sullivan
Chief Pharmacy Officer
Clinical Quality and Care Transformation
Washington State Health Care Authority